PDCD1 and neoplasm: A selective inhibitor of class IIa HDAC, which affects gene expression in monocytes but not lymphocytes, was found to alter the TME by repolarizing TAM in a breast cancer mouse model, resulting in reduced tumor burden and metastasis, both alone and in synergy with PD-1 inhibitor therapy [150].